{"id":789544,"title":"NACI Rapid Response interim guidance on the use of Imvamune in the context of monkeypox outbreaks (mpox) in Canada, CCDR 48(7/8) - Canada.ca","sourceCode":"phac","sourceName":"Public Health Agency of Canada","language":"en","captureDate":"2026-02-26","captureTimestamp":"2026-02-26T01:17:15.575000+00:00","jobId":7,"originalUrl":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2022-48/issue-7-8-july-august-2022/summary-national-advisory-committee-immunization-naci-rapid-response-interim-guidance-imvamune-monkeypox-outbreaks-canada.html","snippet":"National Advisory Committee on Immunization (NACI) rapid response guidance on the use of Imvamune for monkeypox outbreak in Canada This publication was published before November 28, 2022. Since then, the World Health Organization began using ‘mpox’ as the preferred term for…","rawSnapshotUrl":"/api/snapshots/raw/789544","browseUrl":"https://replay.healtharchive.ca/job-7/20260226011715/https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2022-48/issue-7-8-july-august-2022/summary-national-advisory-committee-immunization-naci-rapid-response-interim-guidance-imvamune-monkeypox-outbreaks-canada.html#ha_snapshot=789544","mimeType":"text/html","statusCode":200,"captureBackend":"playwright_warc","captureFidelity":"fallback"}